계명대학교 의학도서관 Repository

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin.

Metadata Downloads
Author(s)
Jong Ho KimSang Soo KimHong Sun BaekIn Kyu LeeDong Jin ChungHo Sang SohnHak Yeon BaeMi Kyung KimJeong Hyun ParkYoung Sik ChoiYoung Il KimJong Ryeal HahmChang Won LeeSung Rae JoMi Kyung ParkKwang Jae LeeIn Joo Kim
Keimyung Author(s)
Kim, Mi Kyung
Department
Dept. of Internal Medicine (내과학)
Journal Title
Diabetes & Metabolism Journal
Issued Date
2016
Volume
40
Issue
3
Keyword
Dipeptidyl peptidase 4 inhibitorMetforminThiazolidinediones
Abstract
Background: We compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an addon
treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes.
Methods: The present study was a multicenter, randomized, active-controlled investigation comparing the effects of vildagliptin
and pioglitazone in Korean patients receiving a stable dose of metformin but exhibiting inadequate glycemic control. Each patient
underwent a 16-week treatment period with either vildagliptin or pioglitazone as an add-on treatment to metformin.
Results: The mean changes in HbA1c levels from baseline were –0.94% in the vildagliptin group and –0.6% in the pioglitazone
group and the difference between the treatments was below the non-inferiority margin of 0.3%. The mean changes in postprandial
plasma glucose (PPG) levels were –60.2 mg/dL in the vildagliptin group and –38.2 mg/dL in the pioglitazone group and
these values significantly differed (P=0.040). There were significant decreases in the levels of total, low density lipoprotein, high
density lipoprotein (HDL), and non-HDL cholesterol in the vildagliptin group but increases in the pioglitazone group. The mean
change in body weight was –0.07 kg in the vildagliptin group and 0.69 kg in the pioglitazone group, which were also significantly
different (P=0.002).
Conclusion: As an add-on to metformin, the efficacy of vildagliptin for the improvement of glycemic control is not inferior to
that of pioglitazone in Korean patients with type 2 diabetes. In addition, add-on treatment with vildagliptin had beneficial effects
on PPG levels, lipid profiles, and body weight compared to pioglitazone.
Keimyung Author(s)(Kor)
김미경
Publisher
School of Medicine
Citation
Jong Ho Kim et al. (2016). Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin. Diabetes & Metabolism Journal, 40(3), 230–239. doi: 10.4093/dmj.2016.40.3.230
Type
Article
ISSN
2233-6079
DOI
10.4093/dmj.2016.40.3.230
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/33168
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.